Sun Pharma shares falls on competition from Glenmark drug

Sep 24 2013, 11:39 IST
Comments 0
'Leading brand in this segment is Taro's Topicort, which had annual sales of $50 million.' (AP) 'Leading brand in this segment is Taro's Topicort, which had annual sales of $50 million.' (AP)
Summary'Leading brand in this segment is Taro's Topicort, which had annual sales of $50 million.'

Shares in India's Sun Pharmaceuticals Industries fall 1 percent as the US Food and Drug Administration approval for Glenmark's Desoximetasone ointment is seen negative for the former's unit, Taro Pharmaceutical Industries Ltd.

Analysts tracking the sector say the leading brand in this segment is Taro's Topicort, which had annual sales of $50 million.

Also, Citigroup in a report says while Taro has also lost market share in its largest product Nystatin/Triam combo, it could see more competition in some of its other products

Ads by Google
Reader´s Comments
| Post a Comment
Please Wait while comments are loading...